Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes
Phase PHASE2
Enrollment 200
Locations 60 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: LY3457263 — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Change from Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-28
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
480-372-5996
Helios Clinical Research - Phoenix
Interventions
  • Drug: LY3457263 — Administered SC
  • Drug: Placebo — Administered SC
Study Locations (60 sites)
Helios Clinical Research - Phoenix, Phoenix, Arizona 85028 United States
Wolverine Clinical Trials, Santa Ana, California 92706 United States
Renstar Medical Research, Ocala, Florida 34471 United States
Oviedo Medical Research, Oviedo, Florida 32765 United States
Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia 30046 United States
Physicians Research Associates, Lawrenceville, Georgia 30046 United States
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City, Georgia 30291 United States
North Georgia Clinical Research, Woodstock, Georgia 30189 United States
Elite Clinical Trials, Rexburg, Idaho 83440 United States
Investigators Research Group, Brownsburg, Indiana 46112 United States
Eligibility Criteria
Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incretins for at least three months prior to screening: * Injectable semaglutide (1 and 2 milligram (mg)) * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg) Exclusion Criteria: * Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma * Have a prior or planned surgical treatment for obesity * Have any of the following cardiovascular conditions within three months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have used insulin to control blood glucose within the past year (short-term use allowed) * Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening * If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study * Have taken any medications or alternative remedies for weight loss within three months prior to screening
Conditions Postpartum Depression
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Postpartum depression is a condition that occurs after birth and is difficult for mothers. Research shows that experiencing postpartum depression once increases the risk of experiencing it in subsequent pregnancies. At the same time, there are findings in the literature that pregnant women with postpartum depression experience mental difficulties, anxiety or depression during pregnancy. For this reason, this study aims to determine the risk of postpartum depression in pregnant women who are pregnant for the first time during pregnancy and to prevent this risk from occurring in the postpartum period. For this purpose, 'Stories to empower mothers' programme was created. This programme was created by researchers who are specialist psychiatric nurses, psychotherapists and art therapists and finalised with expert opinions. The programme consists of six sessions. The sessions are individual and are conducted online except for the first session. A storybook is formed at the end of the programme with the steps followed during the sessions. While creating this storybook, the themes of self-knowledge, defining the situation, identifying difficulties, identifying sources of help, discovering strengths and creating new coping strategies are addressed by using art therapy techniques. The aim of the study is to examine the effect of the 'Stories Empowering Mothers Programme' on the risk of postpartum depression in pregnant women experiencing their first pregnancy. The research is conducted in a non-randomised experimental follow-up research design. Pregnant women who meet the inclusion criteria of the study can be included in the experimental or control group according to their wishes. The data collection process in the study proceeds in the order of determining the target group, pre-test (24-32nd gestational week), post-test (after 5 weeks), follow-up one test (postpartum 2nd-4th week) and follow-up two tests (postpartum 10th-12th week). The data are obtained with the Case Report Form and Postpartum Information Form prepared by the researcher and EPDI, BDI and Brief Psychological Resilience Scale forms. Expert support will be obtained for statistical analyses. Ethics committee permission was obtained before the research was started to be conducted. The research is a doctoral thesis supported by TÜBİTAK.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Stories that Empowered Mother — this intervention is made by resercher for this research.

Primary Outcomes

  • Case Report Form (24 - 32. gestational week)
  • Edinburgh postpartum depression scale (pre-test( 24 - 32. gestational week), post-test( (30 to 38 weeks of gestation, 6 weeks after the pretest) , follow-up 1 test, (2 - 4. postnatal week), follow-up 2 test (10 -12. postanal week))
  • Beck Depression Inventory (pre- test( 24 - 32. gestational week),)
  • Brief Resilience Scale (pre-test( 24 - 32. gestational week), post-test(30 to 38 weeks of gestation, 6 weeks after the pretest))
  • Postpartum Information Form (Follow-up 1 test, (2 - 4. postnatal week))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-04-01
Completion: 2025-11-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ege University
Collaborators: The Scientific and Technological Research Council of Turkey
Contact Information
Study Contact:
Ege M Topcu, Research Asst.
05512030536
ege.miray.eyrenci@ege.edu.tr
Interventions
  • Behavioral: Stories that Empowered Mother — this intervention is made by resercher for this research.
Study Locations (1 sites)
Ege University, Izmir, 35100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * First pregnancy, * Singleton pregnancy, * Gestational week between 24-32, * Regular doctor follow-up, * Scored ≥ 10 on the EDBS, * Scored \< 17 on the BDI, * Literate, * No disability in sensory organs that would prevent communication, * Owning a smart phone or computer, * Having internet access, * Volunteering Exclusion Criteria: * Being in the first trimester of pregnancy, * Being treated/therapized with any psychiatric diagnosis, * Having a risky pregnancy, * Being at risk of premature birth and developing it, * Having any complications related to pregnancy (gestational diabetes, hypertension, bleeding, etc.), * The baby is not healthy, * Developing complications during and after birth, * The baby needs intensive care after birth, * Having a baby lost, * Having a premature birth (\<37 weeks), * The mother has experienced serious daily life difficulties (disaster, loss, etc.), * Not attending three or more of the six sessions
Conditions Asthma Intermittent, Uncontrolled
Phase NA
Enrollment 600
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to deliver a definitive randomised controlled trial to measure the effectiveness and assess cost-effectiveness of a digital social intervention for patients with asthma, composed of promoting engagement with online peer support in a primary care consultation, followed by engagement with online peer support for 12 months. The main questions/objectives this study aims to answer/address are: * Does promoting engagement with an online health community in primary care help people with troublesome asthma to experience fewer asthma symptoms? * To assess cost-effectiveness of the intervention (including quality of life, well-being, use of healthcare services etc); stakeholder satisfaction (patients and healthcare professionals) with the intervention; fidelity of protocol delivery; context in which positive outcomes can be triggered.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: A digital social intervention by primary care clinicians — * Signposting to the online health community by explaining different sections of the website. * Introducing norms and values for passive (just reading) and active (writing posts) participation. * Motivation for engagement with the online health community, emphasising that it could be used ad hoc (e.g. when feeling unwell, or when they need information or emotional support). * Problem solving with respect to any difficulties/concerns. * Signing patients up to the online health community, by explaining terms and conditions. * Explaining the differences between posting publicly and privately (public posts are shared with third parties whereas private messages to other users are not shared). * Collection of baseline measures. Data will be entered into the study's online database. Patients will leave the consultation with a leaflet summarising all procedural matters in relation to signing up with the online health community and a reminder of their username and password.

Primary Outcomes

  • Control of asthma (Baseline and very three months in a 12 month follow-up period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-25
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Queen Mary University of London
Collaborators: National Institute for Health Research, United Kingdom, City, University of London, University of Cambridge, University of Edinburgh, University of Nottingham, University of Surrey, St George's, University of London, Asthma UK
Principal Investigators:
  • Anna De Simoni, PhD (PRINCIPAL_INVESTIGATOR) - Clinical Reader in Primary Care Research, Queen Mary University of London
Contact Information
Study Contact:
Anna De Simoni, PhD
+442078822520
a.desimoni@qmul.ac.uk
Georgios Karampatakis, PhD
g.karampatakis@qmul.ac.uk
Interventions
  • Behavioral: A digital social intervention by primary care clinicians — * Signposting to the online health community by explaining different sections of the website. * Introducing norms and values for passive (just reading) and active (writing posts) participation. * Motivation for engagement with the online health community, emphasising that it could be used ad hoc (e.g. when feeling unwell, or when they need information or emotional support). * Problem solving with respect to any difficulties/concerns. * Signing patients up to the online health community, by explaining terms and conditions. * Explaining the differences between posting publicly and privately (public posts are shared with third parties whereas private messages to other users are not shared). * Collection of baseline measures. Data will be entered into the study's online database. Patients will leave the consultation with a leaflet summarising all procedural matters in relation to signing up with the online health community and a reminder of their username and password.
Study Locations (5 sites)
South West Peninsula Regional Research Delivery Network, Exeter, United Kingdom
East Midlands Regional Research Delivery Network, Leicester, United Kingdom
North London Regional Research Delivery Network, London, United Kingdom
North East and North Cumbria, Newcastle upon Tyne, United Kingdom
East of England Regional Research Delivery Network, Norwich, United Kingdom
Eligibility Criteria
Inclusion Criteria: To participate in the study, participants will need to: * Be adult asthma patients (aged 18 to 99) who have expressed their interest in digital social interventions in the recruitment survey. * Report troublesome asthma (i.e. an ACT score of less than 20) in the recruitment survey). * Be competent to consent for themselves, as determined by the healthcare professional delivering the consultation. There are no specific criteria for selecting participants for the exit interviews (a convenience sample of patients and clinicians will be used and recruitment will continue until data saturation). Exclusion Criteria: * Patients who are already members of the Asthma + Lung UK online health community or other asthma online health communities/Facebook groups (i.e. general use of social media will not prevent participation). * Palliative or end of life patients. * Patients receiving institutional long-term care (receiving total care in residential homes or living in nursing homes). * Patients considered unsuitable to take part in the study by their general practitioners/nurses. There are no specific criteria for selecting participants for the exit interviews (a convenience sample of patients and clinicians will be used and recruitment will continue until data saturation).
Conditions Breast Cancer, Breast Cancer Stage II, B...
Phase NA
Enrollment 700
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Remote Simultaneous Medical Interpreting/RSMI — Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.
  • Other: Remote Consecutive Medical Interpreting/RCMI — Remote Consecutive Medical Interpreting (RCMI; "audio consecutive"), is the most commonly utilized remote interpreting
  • Other: Remote Consecutive Video Medical Interpreting/RCVI — Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter

Primary Outcomes

  • Number of interpretation errors (up to 30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-02
Completion: 2029-12-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Francesca Gany, MD, MS (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Francesca Gany, MD, MS
646-888-8054
ganyf@mskcc.org
Lisa Diamond, MD
646-888-8061
diamondl@mskcc.org
Francesca Gany, MD, MS
646-888-8054
Memorial Sloan Kettering Basking Ridge (Consent Only)
Interventions
  • Other: Remote Simultaneous Medical Interpreting/RSMI — Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.
  • Other: Remote Consecutive Medical Interpreting/RCMI — Remote Consecutive Medical Interpreting (RCMI; "audio consecutive"), is the most commonly utilized remote interpreting
  • Other: Remote Consecutive Video Medical Interpreting/RCVI — Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter
Study Locations (8 sites)
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk- Commack (Consent Only), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York 10604 United States
Memorial Sloan Kettering at Ralph Lauren Center (All Protocol Activities), New York, New York 10035 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: Phase I Patients * Age \>=18 years (per EMR) * Preferred language for healthcare is Spanish or Mandarin (per self-report) * Limited English Proficient; cannot speak English "very well" (per self-report) * Diagnosis of breast cancer or gastrointestinal (per EMR) * Will be visiting MSK oncology teams for the first or second appointment (per EMR) * Agrees to be audio-recorded (per self-report) Phase 1 Providers * Breast or gastrointestinal cancer provider who sees patients (e.g., breast or gastrointestinal oncologists, advanced practice providers, and/or nurses) * Does not speak Spanish and/or Mandarin; providers who speak one language and not the other may participate (e.g., speaks Spanish but not Mandarin) (per self-report) * Agrees to be audio-record (per self-report) Phase 2 (clinic staff only; patient participants will be drawn from Phase 1) * Is a staff member who works/worked in one of the study clinic sites during the period of Phase 1 RCT study activities * Agrees to be audio-recorded (per self-report) Exclusion Criteria: Phase 1 Patients * Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team) * Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team) Phase I Providers * None Phase 2 (clinic staff only; Phase 1 patient participants follow above criteria) * None
Conditions Depression - Major Depressive Disorder
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to estimate the prevalence and severity of depression among patients with coronary artery disease (CAD) in Baghdad, Iraq, using the self-administered PHQ-9 questionnaire. The study seeks to answer the following questions: What is the prevalence of depression among CAD patients? How is the severity of depression distributed within this group? Are specific demographic, clinical, or environmental factors associated with higher levels of depression? Participants will: Complete the PHQ-9 to assess the severity of depressive symptoms at a specific point in time. Provide demographic and clinical information, including age, gender, socioeconomic status, comorbidities, and CAD-related factors such as type of intervention and duration of illness, to explore potential correlations with depression.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of Depression (Data collection will occur over a 3-month period, with each participant completing the assessment at a single point during this time frame.)
  • Severity of Depression (Data collection will occur over a 3-months period, with each participant completing the PHQ-9 assessment at a single point during this time frame.)
  • Patient Health Questionnaire-9 (PHQ-9) (Data collection will occur over a 3-months period, with each participant completing the PHQ-9 assessment at a single point during this time frame.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-20
Completion: 2025-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Al-Nahrain University
Principal Investigators:
  • Aws Al-Rubaye Lecturer, Internal Medicine (STUDY_DIRECTOR) - College Of Medicine - Nahrain University
Contact Information
Study Contact:
Abdul-Ilah R. Khamis
+9647838571013
allaabed987@ced.nahrainuniv.edu.iq
Aws Al-Rubaye lecturer, Internal Medicine
+9647730288897
awsalrubaye@nahrainuniv.edu.iq
College of Medicine - Al-Nahrain University
Abdul-Ilah R. Khamis
College of Medicine - Al-Nahrain University
Interventions
N/A
Study Locations (1 sites)
College of Medicine - Al-Nahrain University, Baghdad, Iraq
Eligibility Criteria
Inclusion Criteria: * Diagnosed with coronary artery disease (confirmed through clinical, imaging, or procedural evidence). * Receiving care at designated hospitals in Baghdad. * Able to understand and complete the PHQ-9 questionnaire independently or with minimal assistance. * Consents to participate in the study. Exclusion Criteria: * Patients with a history of severe psychiatric disorders unrelated to depression (e.g., schizophrenia, bipolar disorder). * Patients with cognitive impairments or neurological conditions affecting their ability to complete the questionnaire. * Those currently hospitalized for acute cardiac events (e.g., myocardial infarction) requiring intensive care. * Individuals unwilling to provide informed consent.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 43
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Carboplatin — Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).
  • Drug: Paclitaxel — 80mg/m2 weekly
  • Drug: Pembrolizumab — 200 mg every 3 weeks for 4 cycles

Primary Outcomes

  • pCR Rate in TNBC patients (18 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-20
Completion: 2028-10-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 43 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Principal Investigators:
  • Abi Siva, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Abirami Sivapiragasam
843-792-9300
sivapira@musc.edu
Casey Charlton
charltoc@musc.edu
Medical University of South Carolina
Interventions
  • Drug: Carboplatin — Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).
  • Drug: Paclitaxel — 80mg/m2 weekly
  • Drug: Pembrolizumab — 200 mg every 3 weeks for 4 cycles
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: 1. Histologically confirmed triple-negative breast cancer (TNBC) or hormone receptor-low invasive breast carcinoma, with clinical anatomic Stage II or Stage IIIA/B disease as defined by the AJCC 8th Edition Breast Cancer Stating System. a) The invasive tumor must be hormone receptor-negative or low, defined as estrogen receptor (ER) and/or progesterone receptor (PR) staining present in ≤10% of invasive cancer cells by immunohistochemistry (IHC). b) HER2-negative disease, defined in accordance with current ASCO-CAP HER2 guidelines. 2. Measurable or evaluable tumor in the breast larger than 1 cm, with or without axillary involvement. 3. Patients with multifocal or multicentric disease are eligible, provided the dominant tumor focus is ER and/or PR ≤10% and HER2 negative. 4. Female or male, age ≥18 years. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 6. Medically fit to undergo curative-intent breast surgery per institutional standard of care. 7. No prior chemotherapy, immunotherapy, radiation therapy, or surgery for the current breast cancer (diagnostic core or vacuum-assisted biopsies allowed). 8. Ability to be followed by a cardiologist and/or primary care physician for optimization of cardiac comorbidities, as needed. 9. Adequate organ function at the time of screening, defined as: a) Hematologic 1. Absolute neutrophil count ≥1,500/µL. 2. Platelet count ≥100,000/µL. 3. Leukocytes ≥3,000/µL. 4. Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L (without erythropoietin dependency and without packed red blood cell transfusion within 14 days prior to testing). b) Renal a. Serum creatinine ≤1.5 mg/dL or creatinine clearance ≥50 mL/min. Note: Patients with creatinine clearance 30-50 mL/min may be enrolled at the discretion of the Principal Investigator, given that paclitaxel is primarily hepatically metabolized and carboplatin dosing can be adjusted to renal function. c) Hepatic 1. AST (SGOT) and ALT (SGPT) ≤2.5 × ULN. 2. Serum albumin ≥3.0 g/dL. 3. Participants without a history of Gilbert's syndrome must meet one of the following: i. Total bilirubin ≤1.5 × IULN, or ii. Total bilirubin \>1.5 × IULN with direct bilirubin ≤ULN. d. Participants with a history of Gilbert's syndrome must have total bilirubin ≤5 × ULN. d) Coagulation a. For patients receiving anticoagulant therapy, PT and/or aPTT within the therapeutic range for the intended use of anticoagulants. b. For patients not receiving anticoagulant therapy, INR, PT, and aPTT ≤1.5 × ULN. 10. Breast and axillary imaging (including ultrasound and MRI) within 42 days (6 weeks) prior to registration. 11. Patients with clinically and/or radiologically abnormal axillary lymph nodes must have pathological confirmation with image-guided core biopsy or fine needle aspiration showing metastatic carcinoma. 12. Patients should undergo staging scans to exclude metastatic disease if any of the following apply: a) Axillary imaging shows two or more abnormal lymph nodes, or b) There are clinical signs or symptoms concerning for metastatic disease, or c) At the treating physician's discretion. 13. Patients with bilateral breast cancer are eligible if both tumors are HER2 negative and all other eligibility criteria are met (eligibility should be determined based on the higher-risk side when applicable). 14. Baseline peripheral neuropathy grade ≤2 (per CTCAE). 15. An individual of childbearing potential must be willing and able to use highly effective contraception from the time of informed consent, throughout study treatment, and for at least 6 months after the last dose of trial therapy. Note: Highly effective contraception is defined as methods with a failure rate \<1% per year when used consistently and correctly, and include: copper intrauterine device (IUD); bilateral tubal ligation/occlusion or other documented surgical sterilization; vasectomized partner with documented azoospermia, provided this is the sole sexual partner; or true sexual abstinence, defined as complete abstinence from heterosexual intercourse, when this is the participant's usual and preferred lifestyle. Use of hormonal contraceptive methods (including combined oral contraceptives, progestin-only pills, injectables, implants, hormonal IUDs, patches, or vaginal rings) is not permitted during the study. 16. Ability and willingness to comply with all study procedures, including scheduled visits, treatment plans, laboratory tests, and other study requirements. 17. Ability and willingness to sign and date written informed consent prior to initiation of any study-specific procedures. 18. Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration. 19. Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated. NOTE: No testing for Hepatitis B is required unless mandated by local health authority. 20. Participants with a history of hepatitis C virus (HCV) must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated. NOTE: No testing for Hepatitis C is required unless mandated by local health authority. 21. Patient is ineligible for anthracycline treatment due to at least one of the following of A, B, C, or D: 1. Individuals identified as being at high risk for cardiotoxicity from anthracycline treatment have one or more of the following characteristics. 1\. Preexisting cardiomyopathy with ejection fraction (EF) between 25-49%. 2. Severe valvular disease on echocardiogram. 3. Previous exposure to anthracyclines. 4. Previous exposure to high dose chest wall radiation \>30Gy. 5. Participants who have experienced myocardial infarction, unstable angina pectoris, an arterial thrombotic event, or stroke, within the last 12 months but not less than 3 months ago. b) Medium or high risk for Congestive Heart Failure (CHF) at 3 years as defined by the Cardiotoxicity Prediction Tool from Ezaz et al. \[24\] c) Patients declining anthracycline therapy after thorough discussion regarding its significant role in treating TNBC. d) Patients who are deemed ineligible for anthracycline due to other medical conditions not listed here, as determined by the primary oncologist and confirmed by the study PI. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Subject is planning to participate, currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. 2. Current diagnosis of metastatic or inflammatory breast cancer. 3. Patients deemed unfit to undergo curative surgery according to the standard of care. 4. Patients who have concomitant and/or previous malignancies within the last 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., ductal carcinoma in situ (DCIS), carcinoma in situ of the cervix) that have undergone potential curative therapy are NOT excluded. 5. History of hypersensitivity to compounds that are similar to carboplatin and paclitaxel. 6. Has received major surgery and has not recovered adequately from the toxicity and/or complications before starting study treatment. 7. Subject has received a live vaccine within 30 days prior to the first dose of study drug.
Conditions Breast Cancer Metastatic
Phase PHASE2
Enrollment 40
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Deruxtecan — Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.

Primary Outcomes

  • Objective Response Rate (After cycle 3, approximately 63 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-20
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Daiichi Sankyo, AstraZeneca, Breast Cancer Research Foundation
Principal Investigators:
  • Adriana Kahn, M.D. (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Laura Kane
773-369-6904
laura.kane@yale.edu
Carl Brown
2037854095
carl.brown@yale.edu
Yale University
Adriana Kahn, MD
Yale University
Interventions
  • Drug: Trastuzumab Deruxtecan — Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
Study Locations (3 sites)
Yale University, New Haven, Connecticut 06511 United States
Emory Winship Cancer Institute, Atlanta, Georgia 30322 United States
University of Rochester Medical Center, Rochester, New York 14642 United States
Eligibility Criteria
Inclusion Criteria: 1. Must be competent and able to comprehend, sign, and date an Institutional Review Board (IRB) approved ICF before performance of any study-specific procedures or tests. 2. Men or women ≥18 years old. 3. Pathologically documented breast cancer that is unresectable or metastatic. 4. 4.Tumor biopsies have always shown HER2-IHC 0 (\<10% membrane staining, including 0 null and 0 ultralow) in all prior biopsies and never previously HER2-positive (IHC 3+ or ISH+) or HER2-low (1+, or 2+ ISH-) on prior pathology testing according to American Society of Clinical Oncology College of American Pathologists (ASCO-CAP) guidelines. 5. Either HR-positive or HR-negative status of the tumor per ASCO-CAP guidelines are allowed. 6. Patients with HR-positive disease must have progressed or be intolerant to CDK 4/6 inhibitors plus endocrine therapy, and patients with HR-negative disease must have received 1 line of therapy in the metastatic setting (progression on or within 6 months of neoadjuvant or adjuvant therapy will be accounted for as 1 line of prior therapy). There is no limit on number of subsequent lines of therapy for study entry. . 7. Patients must have never been previously treated with any anti-HER2 therapy, including prior trastuzumab deruxtecan, other HER2-directed ADCs, HER2 antibodies or HER2 tyrosine kinase inhibitors 8. Clinical or radiologic progression (during or after most recent treatment) or intolerance to therapy prior to enrollment in this trial 9. Adequate archival tumor sample \<3 years-old available for assessment of HER2 status by IHC and by HS-HER2 quantitative assay. If archival tissue is not available or inadequate for assessment (e.g. decalcified bone, cytology, or other), a newly obtained biopsy from a metastatic site (or breast tissue if locally advanced/unresectable disease as the only site of advanced disease) is required on enrolment. 10. Presence of at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 11. ECOG PS ≤ 2. 12. Left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to C1D1. 13. Adequate bone marrow function (Table 1) within 28 days before C1D1, defined as: 1. Platelet count \>≥100,000/mm3 (Platelet transfusion is not allowed within 1 week prior to Screening assessment). 2. Hemoglobin level ≥9.0 g/dL (red blood cell transfusion is not allowed within 1 week prior to Screening assessment). 3. Absolute neutrophil count ≥1500/mm3 (granulocyte colony-stimulating factor administration is not allowed within 1 week prior to Screening assessment). 14. Adequate renal function (Table 1) within 28 days before C1D1, defined as: a. Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft-Gault Equation. 15. Adequate hepatic function (Table 1) within 28 days before C1D1, defined as: 1. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3×ULN (\< 5×ULN in participants with liver metastases). 2. Total bilirubin ≤1.5 × ULN if no liver metastases or \<3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. 16. Adequate blood clotting function( defined below) within 28 days before C1D1, defined as International normalized ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN. 1. Platelet function greater than or equal to 100000/mm3 (Platelet transfusion is not allowed within 1 week prior to C1D1). 2. Hemoglobin greater than or equal to 9.0 g/dL NOTE: Participants requiring ongoing transfusions or growth factor support to maintain haemoglobin ≥9.0 g/dL are not eligible. Red blood cell transfusion is not allowed within 1 week prior to C1D1. 3. Absolute neutrophil count greater than or equal to 1500/mm3. (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1). 4. Alanine aminotransferase and aspartate aminotransferase less than or equal to 3×ULN (\< 5×ULN in participants with liver metastases). 5. Total bilirubin less than or equal to 1.5×ULN if no liver metastases or \< 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. 6. Serum albumin greater than or equal to 2.5 g/dL 7. Creatine clearance greater than or equal to 30 mL/min as determined by Cockcroft Gault (using actual body weight). 8. International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time less than or equal to 1.5 x upper limit of normal 17. Adequate treatment washout period before C1D1, defined below: 1. Major surgery minimum washout period of greater than or equal to 4 weeks 2. Radiation therapy including palliative stereotactic radiation therapy to chest minimum washout period greater than or equal to 4 weeks 3. Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation minimum wash out period of greater than or equal 2 weeks 4. Anti-Cancer chemotherapy \[Immunotherapy (non-antibody based therapy)\], hormonal therapy, antibody-based therapy, or retinoid therapy minimum washout period greater than or equal to 3 weeks 5. Anti-Cancer chemotherapy \[Immunotherapy (non-antibody based therapy)\], hormonal therapy, antibody-based therapy, or retinoid therapy minimum washout period greater than or equal 3 weeks 6. Targeted agents and small molecules minimum washout period greater than or equal 2 weeks or 5 half-lives, whichever is longer 7. Cell-free and Concentrated Ascites Reinfusion Therapy (CART), peritoneal shunt or drainage of pleural effusion, ascites or pericardial effusion minimum washout period greater than or equal to 2 weeks prior to screening assessment 8. Any monoclonal antibody treatment minimum washout period greater than or equal to 3 elimination half-lives of the inhibitor/antibody 18. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of T-DXd. Women of childbearing potential are defined as those who are not surgically sterile (i.e. underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. 19. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 3 from the time of screening (those using hormonal methods must have been stable on their chosen form of contraception for 3 months prior to study entry) and must agree to continue using such precautions for 7 months after the last dose of T-DXd. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of T-DXd. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. 20. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom from screening to 4 months after the final dose of T-DXd. Complete heterosexual abstinence for the duration of the study and drug washout period
Conditions HR+ Breast Cancer
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with hormonal therapy are the current standard frontline treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER-2)-negative metastatic breast cancer (MBC). However, the optimal treatment after progression on CDK4/6 inhibitors remains unknown. Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. This study aimed to evaluate the safety and efficacy of anlotinib-based combination therapy in patients with HR+ MBC previously treated with a CDK4/6 inhibitor.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Interventions / Regimen

  • Other: Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc — Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.

Primary Outcomes

  • Progression free survival (PFS) (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-05
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Quchang Ouyang
15676789890
tgzybc@163.com
Li
15616453102
tgzybc@163.com
Hunan Provincial Tumor Hospital
Interventions
  • Other: Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc — Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.
Study Locations (1 sites)
Hunan Provincial Tumor Hospital, Changsha, Hunan China
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 75 years, with an ECOG score of 0-1, and an expected survival of at least 3 months; * Presence of measurable lesions as defined by RECIST 1.1 criteria; * Histopathologically confirmed HR-positive/HER2-negative breast cancer. HER2 negativity is determined by an immunohistochemistry (IHC) result of HER2 (0/1+). If the result is HER2 (++), a FISH or CISH test is required to confirm the absence of HER2 amplification; * Patients who have undergone multiple lines of advanced therapy with no remaining standard treatment options; * Prior treatment with at least one line of CDK4/6 inhibitors and endocrine therapy; * Disease progression following aromatase inhibitor (AI) or fulvestrant combined with CDK4/6 inhibitors, either as adjuvant therapy or as systemic treatment for advanced disease. Exclusion Criteria: * Patients with HER2-positive breast cancer confirmed by histology or cytology; * Patients who discontinued therapy due to non-disease progression reasons, such as adverse events or other non-medical factors; * Detection of a second primary malignant tumor at the time of enrollment; * Failure to complete CDK4/6 inhibitor therapy; * Pregnant or breastfeeding patients; * Presence of third-space fluid accumulation (e.g., pleural effusion, ascites, pericardial effusion) that cannot be managed through drainage or other methods; * Patients previously treated with anti-angiogenic agents, including small molecules such as anlotinib or apatinib, and large molecules such as bevacizumab; * Patients currently receiving any other anti-tumor treatment for any other malignancies.
Conditions Depressive Disorder, Emotional Dysregula...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to examine the effects of a music therapy program in adolescents aged 13-18 years old with emotional difficulties, primarily depression and possibly concurrent diagnoses of anxiety. The main questions are: * What recruitment methods, barriers, and facilitators influence study participation among adolescents with emotional difficulties receiving music therapy in the present study? * Does music therapy contribute to a significant reduction in depression and anxiety symptoms, inclusive concomitant symptoms? * How do adolescents with emotional disorders perceive participation in music therapy, and how do they articulate its potential impacts on their health and well-being? Participants will be invited to participate in a music therapy program, in addition to standard treatment given (TAU). They meet individually in the clinic with a professional music therapist once a week over a period of ten weeks. They will also do musical home exercises between the sessions. Psychiatric interviews and clinical assessments will be conducted before treatment. Assessments and questionnaires will be performed right after the therapy program and three months after ended therapy. There will also be conducted qualitative interviews with a subgroup of the participants.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: psychotherapy — Music therapy

Primary Outcomes

  • Beck's Depression Inventory (The inventory will be assessed at three time points: at baseline, one week post-intervention, and three months post-intervention)
  • The Satisfaction Scale (The scale will be used at two time points: one week post-intervention, three months, post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-09
Completion: 2028-06
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oslo University Hospital
Collaborators: Norwegian Academy of Music
Principal Investigators:
  • Anne M Myhre, MD Phd (PRINCIPAL_INVESTIGATOR) - Oslo UH
Contact Information
Study Contact:
Anne M Myhre, MD Phd
+47 95105059
uxmyan@ous-hf.no
Kristin R Øvergaard, MD Phd
+47 61748301
UXVKRI@ous-hf.no
Anne M Myhre, MD phd
95105059
uxmyan@ous-hf.no
Oslo university hospital
Interventions
  • Other: psychotherapy — Music therapy
Study Locations (1 sites)
Oslo university hospital, Oslo, Nydalen 0424 Norway
Eligibility Criteria
Inclusion criteria: * adolescents 13 to 18 years * emotional difficulties Exclusion criteria: * autism spectrum disorder * mental retardation * severe depressive episode combined with high suicidal risk
Conditions Perimenopause, Hypertension
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to study the effects of 12 weeks of melatonin supplementation compared to placebo in women who are in the menopause transition (perimenopause) and have high blood pressure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Terry Naturally® melatonin 5mg SR — Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
  • Dietary Supplement: Placebo — Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.

Primary Outcomes

  • Change in Nocturnal Systolic Blood Pressure (SBP) (Measured at baseline and at the end of the 12-week intervention)
  • Change in Nocturnal Diastolic Blood Pressure (DBP) (Measured at baseline and at the end of the 12-week intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-23
Completion: 2028-01
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Naima Covassin, Ph.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Perimenopause Study Team
507-255-8897
PerimenopauseStdy@mayo.edu
Naima Covassin, Ph.D.
Covassin.Naima@mayo.edu
Mayo Clinic in Rochester
Naima Covassin, Ph.D.
Mayo Clinic in Rochester
Interventions
  • Dietary Supplement: Terry Naturally® melatonin 5mg SR — Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
  • Dietary Supplement: Placebo — Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria * Age 40-55 years old * Female individuals with intact uterus and at least one ovary * Hypertension o Defined as a prior diagnosis of hypertension, use of antihypertensive agents, or office SBP/DBP ≥130/80 mmHg * On stable medical regimen (≥ 2 months) if taking other medications Exclusion Criteria * Prescription sleeping medications or melatonin supplementation * Pregnant or lactating * Use of tobacco, nicotine or vaping products * Night shift work * On prescription aspirin * Severe lactose intolerance * History of substance use disorder * History of suicidal ideation * History of clinically diagnosed anemia (within the past 5 years) or low hemoglobin levels (\<11.6 g/dL) within the past 12 months * Active cancer * Severe daytime sleepiness (score \>15 at the Epworth Sleepiness Scale \[ESS\])81 * Current or recent (within the past 2 months) participation in other research studies at the discretion of study investigators * Inability to provide written consent and/or to speak and read English * Any other medical, geographic, or social factor making study participation impractical
Conditions Inflammation, Obesity and Type 2 Diabete...
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to evaluate the inflammatory response associated with cardiometabolic diseases, and whether these can be reduced by ex vivo treatment with therapeutic agents. Briefly, the study involves two populations: healthy volunteers and severely obese patients undergoing weight-loss surgery. The main questions the study seeks to address are: 1. To investigate if the therapeutic agents modulate the inflammatory response linked to obesity and cardiometabolic disease? 2. What underlying factors contribute to variations in individual responses? Researchers will examine differences between healthy participants and those undergoing weight-loss surgery to assess the potential impact of weight loss on responsiveness and overall outcomes. Participants will: * Undergo initial testing to evaluate their baseline response. * Provide samples during surgery for further analysis. * Participate in follow-up assessments to track changes over time.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Gastric bypass — Roux-en-Y gastric bypass or sleeve gastrectomy

Primary Outcomes

  • Whole blood ROS prooduction (At baseline and 1 year post surgery)
  • Whole blood ROS production (At the time of enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-30
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Principal Investigators:
  • Emma Börgeson, Dr., PhD, MSc (PRINCIPAL_INVESTIGATOR) - University of Aarhus
Contact Information
Study Contact:
Emma Börgeson, MSc
+45 9352 2984
emma.borgeson@biomed.au.dk
Emma Börgeson, PhD, associate professor
+45 9352 2984
emma.borgeson@biomed.au.dk
Steno Diabetes Center Aarhus
Interventions
  • Procedure: Gastric bypass — Roux-en-Y gastric bypass or sleeve gastrectomy
Study Locations (1 sites)
Steno Diabetes Center Aarhus, Aarhus, 8200 Denmark
Eligibility Criteria
Inclusion Criteria: * Individuals willing and able to give appropriate oral and written informed consent * Men and women over 18 years of age. * Correct body mass index (BMI) (Lean controls: 18.5-24.9 kg/m2. Obese gastric bypass patients: 35-50 kg/m2) Exclusion Criteria: * The individual does not follow instructions given in the research study. * Pregnancy. * Significant gastrointestinal problems. * Use of tobacco. * The individual consumed alcohol within two days prior to the study visit * Active cancer within 5 years. * Use of dietary supplements that impact the inflammatory resolution process (e.g., fish oils), and the person is not willing to discontinue the use of the supplements 1 week prior to the visits. * Underlying cardiometabolic disease, or medication related to such disease (e.g., blood pressure medication, insulin to treat diabetes, etc.). * Underlying inflammatory disease, or medication related to such disease. * The individual states that they have increased bleeding tendency or are using anti-coagulant (blood-thinning) medication. * For obese patients only: The individual has lost more than 8% of his/her body weight since their clinical referral for surgery or has lost more than 3% of his/her body weight in the 4 months leading up to surgery.
Conditions Diabetes Type 1, Diabetes Type 2 on Insu...
Phase NA
Enrollment 154
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

EkiYou-Study-2 is an interventional multicenter randomised controlled clinical investigation according to EU 2017/745. It is conducted in 154 adults with diabetes and treated by multiple daily insulin injections that will be followed for 6 months. After a randomization, participants will receive for 6 months EkiYou V2 Digital Therapy that will help them to estimate their daily bolus and basal insulin doses. This device weekly adjusts insulin parameters including : basal insulin dose, insulin to carb ratios and correction factor. The control group will stay with their standard care, and after the first three months of control period, they will receive EkiYou V2 for the last three months. The aim of this study is to examine the performance of the EkiYou V2 Digital Therapy compared with conventional methods for people with diabetes treated with multi-injections as part of a basal-bolus regimen. We also aim to assess the level of satisfaction and user experience with the EkiYou application, as well as the quality of life of study participants.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: EkiYou V2 — Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose. The device includes the following features to participants: * Carbohydrate counting through an extensive food database with more than 200k items. * Bolus calculation based on their meal, physical activity and blood glucose. * Bolus correction advice. * Long-acting insulin reminders and automatic periodic titration. * Insulin-to-carb ratios and correction factor automatic adjustment.

Primary Outcomes

  • Change in the percentage of time in range 70-180 mg/dL (At three Month Versus Inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-05
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 154 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: DiappyMed
Collaborators: Sanoia
Contact Information
Study Contact:
Omar Diouri, PhD
+33 6 27 17 79 49
omar.diouri@diappymed.com
Emmanuel Cosson
emmanuel.cosson@aphp.fr
APHP Avicennes
Michael Joubert
joubert-m@chu-caen.fr
CHU CAEN
Interventions
  • Device: EkiYou V2 — Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose. The device includes the following features to participants: * Carbohydrate counting through an extensive food database with more than 200k items. * Bolus calculation based on their meal, physical activity and blood glucose. * Bolus correction advice. * Long-acting insulin reminders and automatic periodic titration. * Insulin-to-carb ratios and correction factor automatic adjustment.
Study Locations (16 sites)
APHP Avicennes, Bobigny, France
CHU CAEN, Caen, France
IDNC, Chartres, France
CHSF Corbeil-Essonnes, Corbeil-Essonnes, France
Cabinet Dr Picard, Dijon, France
GH Le Havre - Hôpital Jacques Monod, Le Havre, France
CHU Limoges - Dupuytren, Limoges, France
Fondation Ambroise Paré / HEM, Marseille, France
Cabinet Dr Navaranne, Mérignac, France
University Hospital, Montpellier, Montpellier, France
Eligibility Criteria
Inclusion Criteria: * be aged 18 or over, * have type 1 or type 2 diabetes or diabetes secondary to pancreatic disease, * have been treated with multi-injection basal/bolus insulin therapy for at least 6 months, * using a compatible rapid insulin with the device Ekiyou such as : Novorapid, Humalog, Apidra, Asparte Sanofi, Fiasp or Lyumjev, * using a compatible long-acting insulin with the device EkiYou such as : Lantus, Abasaglar, Toujeo, Levemir or Tresiba, * have been using a continuous glucose monitoring device such as Dexcom G6, Dexcom One, Dexcom One+ or FreeStyle Libre for at least 3 months, * have given their physician access to their glucose data via a glucose data management platform, * for type 2 diabetic patients using an hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors), have no change in dosage regimen for at least 3 months * have recorded at least 70% of CGM data over a 14-day window close to the inclusion date, * have at least one smartphone running Android 5.0 or higher or iOS 12.0 or higher connected to the internet and able to receive CGM data available to them on the day of the inclusion, * able to read or use a smartphone with no visual impairment needing specific typography, * for patients of childbearing potential, a pregnancy test must have been carried out prior to inclusion, or an effective and adequate method of contraception must be used, * be affiliated to a French social security scheme. Exclusion Criteria: * pregnant or breast-feeding women, * type 1 diabetic patients treated with any hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors), * insulin-resistant patient: prescribed daily insulin dose \> 1 U/kg/day or \> 200 U/day, * patient with very low insulin requirements: daily insulin dose \< 15 U/day, * patient with gastroparesis, * diabetic ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within the 6 months prior to inclusion, * pancreatic disease secondary to chronic ethanolism, * known medical condition that, in the investigator's opinion, may interfere with the protocol, * patient who cannot be monitored for 3 months, * intellectual ability compromising use of the application, comprehension or completion of questionnaires, * participation in another clinical trial or administration of a non-authorised drug in the 4 weeks preceding the screening, * person taking part in another research study with an exclusion period still in progress, * under guardianship or curatorship, * imprisoned or otherwise deprived of liberty.